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1 
ABSTRACT  
Here I report data to support a tumor suppressor role of the Cl 2 gene. Indeed, I 
detected a drastic reduction, of Cl 2 gene expression in almost all thyroid 
carcinomas analyzed, with respect to normal thyroid, with the lowest expression 
levels observed in the follicular variants of papillary carcinomas. Loss of 
heterozygosity and CpG hypermethylation at the second exon likely accounts for 
Cl 2 downregulation in thyroid carcinomas. A drastic reduction in Cl 2  
expression, with respect to normal counterpart tissues, was also observed in 
breast, colon and ovarian carcinomas. The restoration of Cl 2  expression in two 
human thyroid anaplastic carcinoma cell lines leads to the suppression of the 
malignant phenotype associated with a higher susceptibility to apoptosis.  
The development of thyroid adenomas and ovarian carcinomas in Cl   knock-out 
mice validates the tumor suppressor role of Cl 2  gene. Finally, transgenic mice 
for RET/PTC1 oncogene crossed with the Cl 2  knock-out mice developed much 
more aggressive thyroid carcinomas compared with those observed in the single 
mutant RET/PTC 1 mice.  
Therefore, these results taken together indicate Cl 2  as a putative tumor 
suppressor gene in the process of human thyroid carcinogenesis. 
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2 INTRODUCTION 
2.1  
Thyroid gland 
The thyroid gland, which is one of the largest endocrine organs in humans, 
regulates systemic metabolism through thyroid hormones. It is composed of 
spherical follicles that selectively absorb iodine from the blood for the 
production of thyroid hormones (T3 and T4). The follicles are surrounded by a 
single layer of thyroid epithelial cells named follicular cells, which synthesize 
and secrete T3 (L-triiodothyronine) and T4 (L-thyroxine) hormones under the 
control of the hypothalamic–pituitary axis with negative feedback by the thyroid 
hormones (Kondo T, 2006) (Figure 1).  
 
Figure 1. Schematic representation of thyroid gland structure and function. 
Thyroid follicular cells synthesize, store and secrete thyroid hormones T3 and T4 under the 
control of the hypothalamic-pituitary axis with negative feedback by the thyroid hormones. 
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Thyrotropin-releasing hormone (TRH), which is secreted from the 
hypothalamus, stimulates the release of thyroid-stimulating hormone (TSH) from 
the anterior pituitary gland. TSH stimulates the follicular cells to synthesize and 
secrete thyroid hormones. Parafollicular cells (or C cells) are in the interstitial 
spaces outside the thyroid follicles and produce the calcium-regulating hormone 
calcitonin. 
 
2.2  
Thyroid cancer 
Tumors are the result of the accumulation of different modifications in critical 
genes involved in the control of cell proliferation. In a large number of 
carcinomas with worst prognosis, lesions are not diagnosed until the disease is at 
an advanced stage. Although various therapeutic approaches are followed in 
clinical practice, most of them are not life-saving. Thyroid nodules can be 
hyperplastic benign adenomas or malignant lesions, and can be derived from 
thyroid follicular epithelial cells or C cells. However, more than 95% of thyroid 
carcinomas are derived from follicular cells (Kondo T, 2006) and are the most 
common endocrine malignancies, with an estimated 25,000 new cases diagnosed 
annually in the United States. Conversely, only 3% of thyroid tumors, referred to 
as medullary thyroid carcinoma (MTC), are of C cell origin. Thyroid neoplasms 
represent a good model for studying the events involved in epithelial cell multi 
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step carcinogenesis because they comprise a broad spectrum of lesions with 
different degrees of malignancy diagnosed on the basis of histological and 
clinical parameters. Follicular cell-derived thyroid tumors include: 1)benign 
adenomas, which are not invasive and very well differentiated; 2) carcinomas, 
which are divided into well differentiated, poorly differentiated and 
undifferentiated types. Well differentiated thyroid carcinomas are papillary 
(PTC) and follicular (FTC) types, being differentiated and having a good 
prognosis (Kondo T, 2006; Saltman B, 2006). Most well-differentiated thyroid 
carcinomas are 2–4 times more frequent in females than in males and manifest in 
patients who are between 20-50 years of age. The papillary carcinoma is defined 
as a malignant epithelial tumor, showing papillar and follicular architecture and 
typical nuclear alterations (Hedinger C, 1989). Particularly, “occult” papillary 
carcinomas are slow-growing and clinically silent carcinomas. PTCs represent 
more than 70% of thyroid malignant tumors and occur two to three-fold more 
frequently in females (Salabe GB, 1994). Exposure to ionizing radiation and 
radioactive contamination of the environment increase the risk of developing this 
kind of cancer as evidenced by the effects of the atomic bombs of Hiroshima and 
Nagasaki (1945), nuclear testing on the Marshall Islands (1954) and Nevada 
(1951–1962), and the more recent nuclear accident in Chernobyl (1986) 
(Nikiforov Y, 1994; Kazakov VS,1992). After the Chernobyl disaster, the effects 
of radiation exposure were most pronounced in children. External beam-
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radiation exposure in childhood for the treatment of benign conditions of the 
head and neck also increased the risk of papillary carcinoma (Ron E, 1995). 
Differently from papillary carcinomas, which can invade local lymphnodes, 
follicular carcinomas are characterized by haematogenous spread and distant 
metastasis. FTCs represent 10% of thyroid carcinomas, are more common in 
females than in males and rarely associated with radiation exposure. A common 
subtype of papillary thyroid carcinoma is the follicular variant of papillary 
thyroid carcinoma (FVPTC). Microscopically, papillary carcinomas are 
characterized by the presence of papillae whereas the follicular variant contains a 
variable area of both papillary and follicular histology. (Hay ID. 1990). These 
tumors contain a predominantly follicular growth pattern but display nuclear 
features and overall clinical behavior consistent with PTC, even though, 
historically, FVPTC has been regarded as more aggressive compared with pure 
PTC (Li Volsi VA, 1994). Poorly differentiated (PDTC) and undifferentiated 
anaplastic carcinomas (ATC) seem to derive from the progression of 
differentiated carcinomas (Van der Laan BF, 1993). Although ATC represents 2-
5% of thyroid malignant tumors, it is one of the most lethal human neoplasms 
being rapidly–growing, very aggressive and always fatal. Anaplastic cancers 
invade adjacent structures and metastasize extensively to cervical lymph nodes 
and distant organs such as lungs and bones. Finally, PDTCs, representing 7% of 
thyroid carcinomas, are morphologically and behaviorally intermediate between 
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well-differentiated and undifferentiated thyroid carcinomas. Medullary 
carcinomas of the thyroid are significantly less common than follicular cell-
derived thyroid tumors and include multiple endocrine neoplasia 2A and 2B 
(MEN2A, MEN2B) and familial medullary thyroid carcinoma. This type of 
thyroid tumor is characterized by gain-of-function mutations of RET proto-
oncogene. 
 
2.3 Genetic lesions in thyroid carcinomas 
2.3.1 
Proto-oncogenes and oncogenes 
The involvement of several oncogenes has been demonstrated in thyroid 
carcinomas (Figure 2). Mutations or rearrangements in genes encoding RET, 
NTRK1, BRAF or Ras are detectable in nearly 70% of all cases in well-
differentiated thyroid carcinoma (Table 1) (Kondo T, 2006). 
 
Genetic alteration PTC FTC PDTC ATC 
RET rearrangement 13-43% 0% 0-13% 0% 
Braf mutation 26-69% 0% 0-13% 10-35% 
NTRK1 rearrangement 5-13% Unknown Unknown Unknown 
Ras mutation 0-21% 40-53% 18-27% 20-60% 
TP53 mutation 0-5% 0-9% 17-38% 67-88% 
 
 
Table 1. Genetic defects in papillary (PTC), follicular (FTC), poorly 
differentiated (PDTC) and anaplastic (ATC) thyroid carcinomas. 
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RET is a transmembrane receptor-tyrosine kinase encoded by RET proto-
oncogene which is rearranged in sporadic and radiation-associated papillary 
carcinoma. The most common RET chimeric genes are H4(CCDC6)–RET (also 
known as RET/PTC1) and ELE1–RET (also known as RET/PTC3) in papillary 
carcinoma (Kondo T, 2006). The neurotrophic receptor-tyrosine kinase NTRK1 
(also known as TRK and TRKA) is another proto-oncogene encoding a 
transmembrane tyrosine-kinase receptor for nerve growth factor rearranged in 5-
13% of sporadic but only 3% of radiation-induced papillary thyroid tumors. 
TPM3, TPR and TFG are the main fusion partners in the chimeric oncogenes 
TRK, TRK-T1,TRK-T2 and TRK-T3 (Kondo T, 2006). BRAF is a 
serine/threonine kinase involved in cell proliferation pathways. BRAFV600E is 
the most common alteration in sporadic papillary carcinomas. BRAF mutations 
are found in 29–69% of papillary thyroid carcinomas, in up to 13% of poorly 
differentiated thyroid carcinomas and 35% of undifferentiated anaplastic thyroid 
carcinomas but not in follicular thyroid carcinomas (Kondo T, 2006). Ras 
mutated is one of the most common genetic lesions found in human tumors. Ras 
proto-oncogenes known as HRAS, KRAS and NRAS play a crucial role in 
thyroid tumorigenesis. A low incidence of Ras mutation was found in well-
differentiated thyroid carcinoma whereas this phenomenon is more frequent in 
poorly differentiated and undifferentiated thyroid carcinoma, thus indicating its 
importance in thyroid tumor progression. The critical role of ras gene activation 
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in some thyroid cancer histotypes was confirmed by the induction of thyroid 
follicular carcinomas associated to lung metastasis following the injection of the 
Kirsten murine sarcoma virus into the thyroid gland of adult Fischer rats 
(Portella G, 1989). The important role of ras oncogenes in thyroid cancer was 
also demonstrated in human follicular and anaplastic carcinoma where the 
frequency of mutation in this gene is about 50% (Nikiforova MN, 2003). Finally, 
PAX8-PPAR-γ rearrangements which juxtapose the thyroid transcription factor 
PAX8 to the peroxisome proliferator-activated receptor (PPAR-γ) and 
impairment of the TP53 tumor suppressor gene were also reported in follicular 
and anaplastic carcinomas, respectively (Kroll TG, 2000; Suarez HG, 1990; 
Fagin JA,1993). Very recently another activated form, called  B-RAF, has been 
reported in irradiated patients of the Chernobyl area, consisting in the in-frame 
fusion of the first eight exons of the A-kinase anchor protein (AKAP9) gene with 
the carboxyl-terminal encoding-region (exons 9-18) of BRAF that results from a 
paracentric inversion [inv (7)q21-22q34] of the long arm of chromosome 7 
(Fusco A, 2005). 
 
2.3.2  
Tumor suppressor genes 
Tumor suppressor genes are normal genes that control cell division, repair DNA 
mistakes, and tell cells when to die. All these processes are required for the 
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normal cell differentiation, organogenesis and tissue homeostasis of all 
multicellular organisms. When tumor suppressor genes do not work properly, 
cells can grow out of control and eventually lead to cancer. The mechanisms that 
may alter the normal function of tumor suppressor genes are numerous. The first, 
and most important, model to explain how the function of a tumor suppressor 
gene may be invalidated was proposed by Knudson in the early 70s (Knudson 
AG, 1971) and provided a two-hit events for gene inactivation. Both copies of a 
tumor suppressor gene should be inactivated either through nonsense or 
truncating mutations. Nevertheless, studies conducted in multiple tumor types 
highlight a new generation of tumor suppressor genes that redefine Knudson's 
hypothesis to include epigenetic inactivation as one or both of the two hits 
required for tumor suppressor gene inactivation (Paige AJ, 2003). Among the 
most important and well studied inactivating epigenetic events, 
hypermethylation of CpG islands in the gene promoter region or in other 
regulatory regions and the lack of an allele (loss of heterozygosity, LOH) may 
account for a reduced expression of tumor suppressor genes, and  as 
consequence, a decreasing of their function. Studies indicate that genetic and 
epigenetic events can work either in combination or in isolation to inactivate 
tumor suppressor genes in cancer. 
In thyroid neoplastic lesions, despite the high frequency of oncogenes activation, 
tumor suppressor genes clearly involved in thyroid carcinogenesis still need to be 
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identified. Impairment of the p53 tumor suppressor gene function, overall 
through nonsense point mutations, represents a typical feature of anaplastic 
carcinomas (Fagin JA, 1993). Decreased levels of PTEN (Bruni P, 2000) and 
PTPRJ (Iuliano R, 2003), a dual specific phosphatase and a receptor tyrosine 
phosphatase, respectively, have been described in thyroid malignancies: both 
these proteins increase the stability of p27(KIP1), which in turn can negatively 
regulate the transition through the cell cycle. Therefore, it is possible say that the 
identification of other genes whose impairment of function might favor thyroid 
cell transformation, represents a prior aim in thyroid cancer research since, until 
now, very little is known about them. 
  
2.4 
The Cl 2 gene 
Our group has recently identified (Visconti R, 2003), by a differential screening 
of PC Cl 3 rat cell lines versus the same cells transfected with the Adenovirus 
E1A (PC E1A), a gene named Cl 2, that was strongly upregulated in PC E1A 
cells. The rat Cl 2 transcript is 4.4 Kb long and encodes a 949 amino acid 
protein. In human thyroid neoplastic cell lines and thyroid carcinomas the 
corresponding orthologues gene was drastically down-regulated, even though the 
number of neoplastic samples analyzed in the study was not exhaustive. To 
explain the contrasting behavior of Cl 2 expression in PC E1A cell lines and 
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thyroid carcinoma, the effects of the E1A adenovirus infection on eukaryotic 
cells have been analyzed. Interestingly, it appears that the same E1A activities 
required for oncogenic transformation also stimulate programmed cell death. 
(Whyte P, 1988; Chinnadurai G, 1992; White E, 1995). Induction of apoptosis 
by E1A adenovirus may explain why the Cl 2 gene was overexpressed in PC E1 
A cell lines. Consequently, based on the pro-apoptotic effects of E1A infection 
and on the finding that in human thyroid carcinoma cell lines and human thyroid 
tumors Cl 2 was down-regulatated, the authors hypothesized that this gene might 
function as a tumor suppressor gene.  
A schematic organization of human Cl 2 protein sequence is shown in Figure 2. 
 
 
Figure 2. Human Cl 2 protein. In grey are indicated the protein segments without known 
motifs. Segment in red indicates a signal peptide; segments in pink indicate nuclear 
localization signals (NLS) ; segment in green indicates coiled coil region; segments in blue 
indicate regions containing repeats. 
 
Bioinformatic analysis of protein sequence shows the presence of nuclear 
localization signals (NLS), Figure 2. These segments are scattered through the 
entire protein aa sequence 493 (PKKK), 550 (KKKK), 584 (KKKK), 73 
(PLQRRRS) 492 (PPKKKAQ), 493 (PKKKAQD), 530 (PLKKAKE), 546 
(PEKEKKK), as well as bipartite NLS at aa 419 (RKDQHRERPQTTRRPSK), 
538 (KKHEKLEKPEKEKKKKM), 570 (KKSEKKSKQEKEKSKKK), 574 
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(KKSKQEKEKSKKKKGGK), 609 (KKSVADLLGSFEGKRRL), and 764 
(KKQSLENFLSRFRWRRR) and are characterized by the presence of lysine-
rich region. 
The presence of a signal peptide (Figure 2) suggested that the protein may be 
secreted. Although the presence of the protein in the culture medium has been 
demonstrated in certain papers (Tremblay F, 2009; Okada T, 2008; Yi Liu, 2004; 
Hong Mu, 2003), a clear demonstration that CCDC80 may be present also in 
extracellular environment requires further investigation because other authors 
have verified that the localization of the protein was exclusively nuclear and/or 
cytoplasmatic (Bommer G, 2004). 
Three regions of the protein (RPT, Figure 2) contain internal repeats. The three 
repeats represented the most highly conserved regions when the human sequence 
was compared with rat and mouse protein and showed an identity ranging form 
91% to 98%. These three regions shared also a homology of about 30% with the 
carboxyl-terminal regions of the human genes “shushi-repeat protein on the X-
chromosome” (SRPX) and “sushi repeat protein upregulated in leukemia” 
(SRPUL). The SRPX gene has been linked to the neoplastic transformation of 
fibroblast and was in fact expressed in normal rat cells, but completely 
suppressed in cells transformed by v-src (Pan J, 1996); whereas SRPUL was 
found normally expressed in heart, ovary, and placenta, but could not be detected 
in leukemic cell lines (Kurosawa H, 1999). Finally, a coiled coil domain is 
present between aa residues 547-587. Many coiled coil type proteins are 
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involved in important biological functions such as the regulation of gene 
expression, e.g. transcription factors. These domains are protein-protein 
interaction domains consisting of two or more alpha-helical motifs twisting 
around each other to form a supercoil (Lupas and Gruber, 2005). The genetic 
locus of Cl 2 in on chromosome 3, 3q13.2. The human protein is 108 kDa. 
In a recent paper (Bommer GT, 2004) was reported the identification of a gene, 
named DRO1, that stays for “Down-Regulated by Oncogenes 1”, which was 
downregulated in rat RK3E epithelial cells neoplastically transformed by -
catenin oncogene, in colon and pancreatic cancer cell lines as well as in few 
cases of human colorectal tumors. These results suggested a possible central role 
of DRO1 in colorectal and pancreatic cancer. The DRO1 gene has a complete 
homology with the human orthologues gene that Visconti and colleagues 
identified in rat thyroid cell lines transfected with E1A adenovirus. Currently, in 
the NCBI database this gene is recorded with the name of Coiled-Coil Domain 
Containing 80 (CCDC80) but it is also known as URB, DRO1, SSG1, okuribin, 
MGC131805, MGC134851. 
Marcantonio M. and colleagues (Marcantonio M, 2001) reported the 
identification of a gene named “steroid-sensitive gene 1” (SSG1) that was 
regulated by estrogen and involved in rat mammary gland cancerogenesis. 
Although they reported the analysis of a protein of only 40-kDa, the open 
reading frame (ORF) cloned by them was identical to the ORF of rat Cl 2 studied 
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by Visconti R. and colleagues. The authors treated intact rats with estrogens and 
then analyzed the mRNA level of SSG1 gene in total RNA from the mammary 
glands and uterus. In mammary gland northern blot indicated high level and no 
significant regulation of SSG1 mRNA in E2-treated samples versus the control 
group, despite down-regulation in the uterus. Corresponding protein samples 
were extracted from mammary gland and uterus tissues and immunoblot was 
performed using an affinity purified anti-SSG1 antibody. In spite of the high 
levels of SSG1 mRNA, SSG1 protein was very low or undetectable in control 
untreated mammary tissue. In contrast, SSG1 protein expression was 
significantly increased by 16-fold in E2-treated rats. Because SSG1 protein levels 
in 7,12-dimethylbenz(a)antracene-induced rat mammary tumors were 23-fold 
greater than SSG1 levels in resting mammary tissue, and 8-fold higher than 
protein levels expressed in lactating mammary glands, the author assumed that 
SSG1 plays a role in estrogen functions, and its overexpression is correlated with 
mammary carcinogenesis. 
Cl 2 has been shown to be upregulated in brown adipose tissue of mildly obese 
bombesin receptor subtype-3 (BRS-3)-deficient mice (Aoki K., 2002). In this 
work the author named the gene Urb (Up Regulated Bombesin) and  suggested 
that it may have a unique function in the regulation of body weight and energy 
metabolism. 
Involvement of Cl 2 in embryogenesis has been proposed by Yi Liu and 
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colleagues studying mouse development. They supported this role mainly by the 
evidence of a temporal expression profile detected in whole mouse embryos of 
various stage using northern blot analysis in which the Cl 2 expression increased 
with the progression of embryogenesis (Yi Liu, 2004). 
Further functions have been proposed for Cl 2 in chicken were it was known as 
Equarin (Hong Mu, 2003). In this work it was shown that microinjection of 
equarin mRNA into Xenopus embryos induced abnormal eye development. The 
authors suggested that equarin was involved in eye formation. 
Finally, in very recent papers the functions of Cl 2 in the adipose tissue and in 
adipogenesis were analyzed (Okada T., 2008; Tremblay F., 2009). Okada and 
colleagues investigated the involvement of the gene in the adipose tissue 
homoeostasis and in obesity. They found that Cl 2 mRNA was predominantly 
expressed in adipose tissue and was downregulated in obese mouse models and 
in diet-induced obese mice. Similar results were confirmed in vitro using 3T3L1 
adipocytes cell lines treated with, insulin, TNF-α, H2O2 and hypoxia which 
caused a reduction of URB mRNA level. Tremblay and colleagues demonstrated 
that Cl 2 is required for the full inhibition of T-cell factor-mediated 
transcriptional activity, down-regulation of Wnt/beta-catenin target genes during 
clonal expansion and the subsequent induction of C/EBPalpha and peroxisome 
proliferator-activated receptor gamma (PPAR. Surprisingly, the author found 
that overexpression of Cl 2 in 3T3-L1 cells also inhibits adipocyte differentiation 
  17 
without affecting the repression of the Wnt/beta-catenin signaling pathway. 
Therefore, they suggested that Cl 2 plays dual roles in adipogenesis by 
mechanisms that involve, at least in part, down-regulation of Wnt/beta-catenin 
signaling and induction of C/EBPalpha and PPAR. 
To validate the potential role of Cl 2 gene in the onset of tumors and in particular 
in thyroid carcinogenesis, in this experimental thesis I have evaluated its 
expression by a quantitative RT-PCR in a larger number of thyroid neoplastic 
samples, and investigated the effects of the restoration of Cl 2 in two human 
thyroid carcinoma cell lines which expressed very low level of this gene. In these 
cell lines I measured proliferation, ability to grow in a semisolid medium and 
invasion potential. In addition, a knock out mouse model for Cl 2 gene was 
generated in order to study the effect of the loss of Cl 2 also in vivo. 
I observed that Cl 2 gene expression was drastically downregulated in thyroid 
carcinomas, particularly in the follicular variant of the papillary carcinomas. 
Consistently, these last samples showed a quite high percentage of LOH at the Cl 
2 locus. Furthermore, the restoration of Cl 2 expression led to the growth 
inhibition of thyroid carcinoma cell lines and to the impairment of their ability to 
grow in soft agar. Finally, the mice null for the Cl 2 gene developed thyroid 
adenomas, ovary carcinomas and when crossed with RET/PTC1 transgenic mice 
the effects on thyroid gland were impressive. This data suggested a critical role 
of the loss of Cl 2 expression in thyroid carcinogenesis. 
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3 
Materials and methods  
Collection of neoplastic tissues 
Thyroid, colon, ovary and breast tumors were collected at the Service 
d’Anatomo-Pathologie, Centre Hospitalier Lyon Sud, Pierre Benite, France. 
Neoplastic human tissues and normal adjacent tissue or the controlateral normal 
thyroid lobe were obtained from surgical specimens and immediately frozen in 
liquid nitrogen. The tumor samples were stored frozen until RNA extractions 
were performed. 
 
RNA and DNA extraction 
Total RNA isolation from human tissues and cell lines was performed with 
Trizol (Invitrogen) according to the manufacturer’s instructions. RNA was 
extracted from fresh specimens after pulverizing on liquid nitrogen using 
stainless steel mortar and pestle. The integrity of the RNA was assessed by 
denaturing agarose gel electrophoresis. To ensure that RNA samples were not 
contaminated with DNA, negative controls were obtained by performing the 
PCR on samples that were not reversed-transcribed but otherwise identically 
processed.  
DNA was prepared for each sample from a portion of liquid nitrogen pulverized 
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tissue using QIAamp DNA Mini Kit (QIAGEN group) following the Tissue 
Protocol of instruction manual. 
 
Real-time PCR 
cDNA preparation. 1 g of total RNA of each sample was reverse-transcribed 
with the QuantiTect Reverse Transcription (QIAGEN group) using an 
optimized blend of oligo-dT and random primers according to the 
manufacturer’s instructions.  
Selection of primers and probes. To design a qRT-PCR assay I used the Human 
ProbeLibraryTM system (Exiqon, Denmark). Using ProbeFinder assay design 
software I chose the best probe and primers pair. All fluorigenic probes were 
dual-labeled with FAM at 5’ end and with a black quencher at the 3’ end. I chose 
probe and primers to amplify a fragment for real-time PCR of Cl 2 mRNA, 
entering its accession number (NM_199511.1) on the ProbeFinder software. I 
chose an amplicon of 60 nucleotides scattered between 5th and 6th exons. The 
number of probe was “human 25” (according to the numbering of Exiquon’s 
Human ProbeLibry kit) and the primer sequences were: Cl 2 forward 5’-
tccctggagaacttcctatcc-3’; Cl 2 reverse 5’-agcagagatcaccagcaacc-3’. The same 
procedure was used to choose both probe and primers for the housekeeping gene 
G6PD, accession number X03674, and for Beta-catenin gene accession number 
NM_001904.3. For G6PD I opted for an amplicon of 106 nucleotides scattered 
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among 3th and 4th exons. The number of probe was “human 05” (according to 
the numbering of Exiquon’s Human ProbeLibry kit) and the primer sequences 
were: G6PD forward 5’-acagagtgagcccttcttcaa-3’; G6PD reverse 5’-
ggaggctgcatcatcgtact-3’. For Beta-catenein I chose an amplicon of 90 
nucleotides scattered among 6th and 7th exons. The number of probe was 
“human 08” (according to the numbering of Exiquon’s Human ProbeLibry kit) 
and the primer sequences were: B-catenin forward 5’-tgttaaattcttggtattacgaca-3’; 
B-catenin reverse 5’-ccaccactagccagtatgatga-3’. 
Relative Quantitative. TaqMan qPCR was performed in 7900HD SDS machine 
(Applied Biosystem, USA) in 384-well plates using a final volume of 20 l. For 
PCR I used 8 l of 2,5x RealMasterMixTM Probe ROX (Eppendorf AG, 
Germany) 200 nM of each primer, 100 nM probe and cDNA generated from 50 
ng of total RNA. The conditions used for PCR were 2 min at 95°C, and then 45 
cycles of 20 sec at 95°C and 1 min a 60°C. Each reaction was performed in 
duplicate. To calculate the relative expression levels I used the 2-CT method 
(Kenneth J, 2001). 
 
Immunohistochemical analysis  
Paraffin sections (5-6 m) were deparaffinized, placed in a solution of absolute 
methanol and 0.3% hydrogen peroxide for 30 min and then washed in PBS 
before immunoperoxidase staining. For Cl 2 immunostaining, I used a 
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commercial polyclonal antibody (anti-URB) purchased by R&D Systems Inc. 
(Minneapolis, USA) produced in goats immunized with the human purified Cl 2 
peptide (Glu 22 - Tyr 650) fused with a 6X histidine tag at the carboxyl-
terminus. The peptide used to produce antibody was sold by the same company. 
The slides were subsequently incubated with biotinylated anti-goat IgG for 20 
min (Dako LSAB2 System) and then with streptavidin horseradish peroxidase 
for 20 min. For immunostaining the slides were incubated in diaminobenzidine 
(DAB-DAKO) solution containing 0.06 mM DAB and 2 mM hydrogen peroxide 
in 0.05% PBS pH 7.6 for 5 min. After chromogen development, the slides were 
washed, dehydrated with alcohol and xylene, and mounted with coverslips using 
a permanent mounting medium (Permount). No staining was also observed when 
the normal thyroid tissues were analyzed after the Cl 2 specific antibodies had 
been pre-incubated with the Cl 2 control peptide (data not shown). Micrographs 
were taken on Kodak Ektachrome film with a photo Zeiss system 
 
Loss of heterozygosity (LOH) analysis 
Five Single Nucleotide Polymorphisms (SNP) that showed high average 
heterozygosity levels, to obtain the highest number of informative cases, were 
chosen using the SNP database of NCBI. To identify the SNPs scattered in the 
genetic locus of Cl 2 I used the putative sequence of URB human gene. The 
SNPs reference, alleles, primers and annealing temperatures used to perform 
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PCR are listed in Table 2. The primers used for PCR were also used for 
sequencing assays. 
 
SNP A.N. Alleles Primer forward Primer reverse Annealing T. 
rs4340680 A/C 5’-catttacatatgttaggaccccatc-3’ 5’-cacattctaatttgtagtttcaagttgtc-3’ 58°C 
rs7349537 A/T 5’-gctacctctcttgattaccctc-3’ 5’-ggaaagtcacagcaagcatg3’ 57°C 
rs10511316 T/C 5’-agctcatccagatcaggctg-3’ 5’-tttcatcactagccagcaccag-3’ 58°C 
rs981181 A/C 5’-gaacccacttgaattacaggag-3’ 5’-gaggttgacgatagtgagac-3’ 56°C 
rs3842905 C/G 5’-ccaacaaggactccttctctactc-3’ 5’-tggcaaaagagggcagcag-3’ 58°C 
 
 
Briefly, genomic DNA was PCR amplified in a region spanning about 400 bp 
around the SNP analyzed, then the purified PCR product was sequenced. I 
measured the height of the two peaks on the chromatogram and calculated the 
ratio of the two alleles in the matched tumor/normal samples: LOH was defined 
if the ratio in the carcinoma sample was <50%.  
 
PCR 
PCR was performed using HotMaster Taq DNA Polimerase (Eppendorf AG, 
Germany) in a final volume of 25 l. For amplification reaction I used 50 ng of 
genomic DNA, 0,5 unit of Hotmaster Taq DNA polymerase, a final 
concentration of each primer of 0.2 M and 0.2mM of dNTPs and 2,5 l of 10x 
HotMaster Taq DNA Polimerase Buffer with Mg2+. The conditions used for PCR 
was an initial denaturation at 94°C for 2 min, 35 cycles of 94°C for 20 sec, 56°-
Table 2. SNP Accession numbers, alleles genotypes, primers and annealing temperature 
used to carry out the LOH analysis on human Cl 2 genomic locus 
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58°C for 10 sec, 70°C for 40 sec and a final extention of 5 min at 70°C. After 
amplification, size and quality of amplicons were checked loading 5 l of 
reactions on agarose gel. 20 l of each PCR was sequenced with specific forward 
and reverse primers used for amplification reaction.  
 
DNA methylation analysis 
Sodium bisulphite conversion of genomic DNA (about 2 g for each conversion) 
was obtained using Epitect Bisulphite kit (QIAGEN group) following the 
purchaser's instructions.  
Pyrosequencing™ analysis: Quantitative DNA methylation analysis was 
performed using the PSQ 96MA instrument from Pyrosequencing (Biotage AB, 
Uppsala, Sweden) following the protocol suggested by the manufacturer. Primers 
used for PCR reactions were: Cl 2 F1 (position from nucleotides -102 to -79) 5’-
ttggaaggggttaaggtattagtt -3’ (5’-Biotinylated); Cl 2 R1(from +89 to +112) 5’-
aactcaaacaacaacaaccactaa -3’. Amplification were carried out on 10 ng of 
bisulphite treated DNA using HotStarTaq DNA polymerase (QIAGEN group) 
under the following conditions: 15 min at 95°C, followed by 50 cycles of 30 sec 
at 95°C, 40 sec at 53,4°C, and 1 min at 72°C, then a final elongation of 10 min at 
72°C before holding at 4°C, in a final reaction volume of 50 l. PCR final 
products (214 bp) were then used for Pyrosequencing reactions; sequencing 
primer (Cl 2 S1) was 5’-acaaatcaacaaaacacc-3’.  
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Bisulphite genomic sequencing: 2 l of each sample were used as template in 
PCR reactions using the following primers: Cl 2 seq F1 5’-
gtggattatataatgatatggagaatggg-3’ and Cl 2 seq R1 5’-cccctaactactaatctttactcaaatc-
3’ for the analysis of Cl 2 CpG islands, which are located on the second exon. 
Amplifications were carried out on 10 ng of bisulphite treated DNA using the 
same protocol described above. PCR final products were then cloned into the 
pGEM-T-easy vector provided by Promega pGEM-T-Easy Vector System II 
(Promega Italia, Milan, Italy) following the supplier’s procedures. The purified 
plasmids were sequenced in both directions using T7 and Sp6 primers. At least 
20 independent clones were sequenced to determine the methylation pattern of 
individual molecules.  
 
Assay of the transformed state  
Soft agar assays were performed according to a previously described technique 
(Montagnier L, 1964). The tumorigenicity of the cell lines was tested by 
subcutaneous injections of 2 x 106cells into athymic mice. The animals were 
monitored at regular intervals for the appearance of tumors. 
 
Generation of Cl 2-KO mice 
We used gene targeting techniques in embryonic stem (ES) cells to generate a 
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null mutation at the murine Cl 2 genomic locus. We deleted exon, which 
contains the start site of the murine Cl 2 gene and replaced them with a 
neomycin-resistant gene. Heterozygous progeny of chimeric animals were 
identified by Southern-blot analysis of EcoRI-digested tail DNA (data not 
shown), and mutants were established to produce mice heterozygous or 
homozygous for the Cl 2-null allele. Both heterozygous and homozygous mutant 
mice were viable and fertile. All mice were maintained under specific pathogen-
free conditions in our Laboratory Animal Facility (Istituto dei Tumori di Napoli, 
Naples, Italy) and all studies were conducted in accordance with Italian 
regulations for experimentations on animals. 
 
Cell cycle analysis.  
Cells were harvested in PBS containing 2 mmol/L EDTA, washed once with 
PBS, and treated for 30 min in cold ethanol (70%). Cells were washed once in 
PBS and permeabilized with 0.2% Tween 20 and 1 mg/mL RNase A for 30 min, 
and washed and stained with 50 µg/ml propidium iodide. Stained cells were 
analyzed with a FACSCalibur (Necton Dickinson), and the data was analyzed 
using a Mod-Fit cell cycle analysis program. 
 
Genaration of CL 2 stable clones  
Thyroid carcinoma cell lines (FRO and KAT-4) were transfected using Arrest-in 
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reagent (Open Biosystems, Huntsville USA) with p3XFLAG-CMV.10 plasmid 
(Sigma, Saint Louis USA) carrying the human full-length coding sequence of Cl 
2 gene (pCMV.10-Cl 2/CCDCD80), and with empty vector. Briefly, I 
transfected 10 g of plasmids in a 100 mm cell culture plate using a ratio 
DNA/Arrest-in of 1:5 following the manual’s instruction of Arrest-in. The 
transfected cells were selected in a medium containing geneticin 1250 g/ml 
(G418; Life Technologies). For each transfection, several G418-resistant clones 
and the mass cell population were isolated and expanded for further analysis. For 
Transient transfection I used the same transfecting agent and the same protocol 
described above. 
 
Generation of mouse embryonic fibroblasts (MFSs) 
MEFs have been established from wild-type, CL 2+/- and CL 2-/- embryos 12.5 
days post coitum. Briefly, after removal of the head and internal organs, embryos 
were rinsed with phosphate-buffered saline (PBS), minced, and resuspended in 
DMEM containing 10% FBS and 2 mM glutamine, and 100 IU/ml penicillin and 
100 µg/ml streptomycin following standard procedures. Cells were grown in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% FBS 
(fetal bovine serum), glutamine, penicillin and streptomycin in a 5% CO2 
atmosphere.  
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Invasion quantification assay 
Invasion assays were performed using 24-well transwell units with 8-m 
polycarbonate Nucleopore filters (Corning, NY). 2x10^4 of Cl 2 stable clone cells 
and the same number of FRO cells were resuspended in 100 ul of medium with 
and without serum and placed in the upper compartment, and 600 l of medium 
with serum were added in the lower compartment. The transwell plates were then 
incubated at 37° for 48h in a humidified atmosphere with 5% CO2. Plates were 
then rinsed with PBS, and non invading cells retained in the upper surface of the 
membrane were removed by a cotton swab. Crystal violet solution was used to 
stain invading cells, located in the lower surface of the membrane. To quantify 
the cells retained by polycarbonate Nucleopore filters both in control and in 
stable clone, I removed the crystal violet from Nucleopore filters using a 1% 
SDS solution and measured the absorbance at 575 nm and calculate the ratio: 
(ABS575 FRO-CloneB / ABS575. FRO cell) X 100. 
 
Directional cell migration in vitro wound healing 
A cell monolayer was cultured until a 85-90% of confluence, respectively for 
FRO-Cl 2 cell and control cells in 60 mm cell culture disks. Using a pipette tip I 
disrupted the cell layer mechanically in order to obtain a section of cell culture 
disk without cells. After the wound, I captured the images at the beginning and 
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after regular intervals during cell migration. I stopped to photograph the plate 
after 20 hours because the different mitotic activity and cell growth speed, 
amgon FRO-Cl 2 stable clone and FRO control cells. clone, could distort the 
data.  
 
Identification of apoptosis Tunel assay 
For the detection of apoptosis I used In Situ Cell Death Detection Kit, TMR red 
(Roche Applied Science Germany) based on TdT-mediated dUTP nick end 
labelling (TUNEL) technique. 25x10^4 FRO cells, for each well, were transiently 
transfected in a 6-well plate with pCMV.10-Cl 2 constuct, empty vector and with 
a vector carrying the EGFP protein to estimate the transfection efficiency. After 
48h from transfection I estimated the transfection efficiency in 40% and started 
the procedure for apoptosis detection following the manual’s instructions.  
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4 
RESULTS 
4.1 
Cl 2 expression is drastically reduced in human thyroid carcinomas. 
A previous analysis of a limited number of human thyroid neoplastic samples 
showed a reduced Cl 2 gene expression in most of the papillary thyroid 
carcinomas (PTC) and in some follicular adenomas (Visconti R., 2003). 
However, for the final assessment of the Cl 2 mRNA expression levels in human 
thyroid neoplasias, I analyzed the Cl 2 expression in a larger number of thyroid 
neoplastic samples including 7 goiters, 10 adenomas , 36 classic papillary 
carcinomas, 33 follicular variants of papillary carcinomas, 8 follicular 
carcinomas, and 8 anaplastic carcinomas by a quantitative RT-PCR assay, as 
described in the Materials and Methods section. The results are shown in Figures 
2 and 3. I placed a cut-off value of ± 2 fold to assign an up- or downregulation. 
The variations between -2 and +2 fold with respect to the controls have been 
considered physiological. With this assume, Cl 2 expression was significantly 
downregulated (≤ 2 fold) in 83.5% (71 out of 85) of carcinomas with respect to 
the normal thyroid tissue. In particular, a drastic reduction in Cl 2 gene 
expression was detected in the follicular variant of papillary carcinomas with an 
average of -54.5 fold. In 8 out of 33 of these neoplasias the fold change was less 
than 60, and in some cases the expression of Cl 2 was almost undetectable. In 
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contrast, the reduction in Cl 2 gene expression was less drastic in the classic 
forms of papillary carcinomas and in anaplastic thyroid carcinomas with an 
average fold-change of -11.4.  
 
 
 
 
 
 
 
 
 
 
 
 
 
All papillary carcinomas analyzed in this study were also screened for the 
presence of the known genetic alterations present in PTCs, i.e. RET/PTC 1 and 
RET/PTC3, B-RAF mutations, TRK-T1 and ras gene family mutations. In 
Figure 4 I show the expression of Cl 2 in the PTCs carrying the activation of 
Figure 2. Quantitative PCR on thyroid tumors. Samples are divided based on their histotype. 
Papillary Thyroid Carcinomas (PTC), Follicular Variant of PTC (FV PTC), Follicular Thyroid 
Carcinomas (FTC), Anaplastic Thyroid Carcinomas (ATC). Values are expressed in fold-change in a 
logarithmic scale with respect to a pool of normal samples which equaled 1. 
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RET and TRK-T1 and mutations in the B-RAF gene. 
 
 
 
 
 
 
Carcinoma samples mutated in B-RAF have a behavior quite similar to the 
samples where the typical genetic alterations for PTCs were not detected, with an 
average fold-change decrease of 4.27. Conversely, the PTCs carrying the 
RET/PTC1 rearrangement did not show a significant downregulation of Cl 2 
expression. Interestingly, Cl 2 was drastically downregulated in the only 2 PTCs 
carrying RET/PTC 3 rearrangements with a fold change of -75,5. 
 
 
 
 
 
 
 
 
Figure 4. Expression analysis of Cl 2 mRNA correlated to oncogenes in thyroid carcinomas 
tumor. The average value of down-regulation in BRAFV600E group was -4.27, in RET/PTC1 
group was -1.98, in RET/PTC3 75.5 and the unique sample that presened a TRK-T1 
rearrangement the value was  -3.72. 
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Figure 3. Expression analysis on thyroid goitre and adenoma of Cl 2  mRNA. There were no 
considerable variations in gene expression in this kind of benign lesions. 
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4.2 
 Analysis of loss of heterozygosity (LOH) at the Cl 2 locus (3q13.2) in thyroid 
neoplastic samples. 
Loss of one allele often accounts for reduced gene expression. Therefore, the 
thyroid neoplastic samples were analyzed for LOH at the Cl 2 locus. I used 5 
SNPs markers to evaluate LOH on chromosome 3 at the Cl 2 locus in 70 cases of 
thyroid carcinomas of different histotypes.  
After the screening of the informative and uninformative cases, I selected 45 
informative cases and the results are summarized in Table 3. The loss of 
heterozygosity at the Cl 2 locus was observed in 16 cases (35,5 %) with the 
highest frequency in the follicular variant of papillary carcinomas (10/20; 50%). 
A lower frequency was observed in the classic PTCs (3 out of 13; 23%). Among 
the 5 informative cases of anaplastic carcinoma samples I observed LOH in 3 
cases: a higher number of cases should be analyzed to have a reliable frequency 
of Cl 2 LOH in this histotype. Conversely, no LOH at the Cl 2 locus was 
observed in the follicular adenoma analyzed (0/6).  
Diagnosis Info.cases LOH % 
Adenoma 7 0 0 
Papillary Carcinoma 13 3 23 
Follicular Variant of Pap. 
Carcinoma 20 10 50 
Anaplastic Carcinoma 5 3 60 
Total 45 16 35,5 
 
Table 3.  LOH analysis. 35,5% of human thyroid carcinomas samples analyzed showed 
an LOH event on genomic locus of Cl 2 
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When I compared Cl 2 expression of the follicular variants of papillary 
carcinomas samples showing or not LOH presence, I found that Cl 2 expression 
was much lower in the cases with LOH (p=0,0011) (Figure 5). Since it has been 
recently reported (Bommer GT, 2005) that Cl 2 gene expression is down-
regulated by beta-catenin, I analyzed the expression of beta-catenin in the 
thyroid tumour samples. As shown in Figure 6, an increased beta-catenin 
expression was detected in all thyroid carcinomas. 
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Figure 5. Correlation of expression levels of Cl 2 between thyroid carcinomas samples without 
LOH (grey bars) and samples with LOH (black bars). The samples with LOH event present a 
greater reduction of Cl 2 mRNA. 
 
Figure 6. Each histogram reports the expression value of Cl 2 (grey bars) and beta-catenin 
(black bars) in the same sample. 
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However, in the samples analyzed there is no significant proportional correlation 
between increase of beta-catenin expression and Cl 2 downregulation, apart from 
few cases. 
 
4.3 
 Methylaton analysis of Cl 2 gene. 
I investigated whether epigenetic mechanisms may contribute to Cl 2 gene 
silencing in thyroid tumors. The analysis of the genomic region surrounding the 
Cl 2 transcriptional start site (TSS), revealed that this region was very poor in 
CpG sites and the closest CpG islands were located about 1200 bp downstream 
the TSS, within the second exon (Figure 7).  
 
 
 
 
 
 
 
 
 
 
Figure 7. Methylation analysis of two putative regulatory CpG islands of Cl 2 gene. 
In the CpG +21 revealed a hyper-methylation in several samples respect to controls. 
Samples were divided base on the histotype. PTC, papillary thyroid carcinoma; FV 
PTC, follicular variant of PTC; ATC, anaplastic thyroid carcinomas. 
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However, I decided to analyze the methylation degree at both regions. The two 
CpG sites located just downstream the TSS (positions +21 and + 41) were 
analyzed for DNA methylation using the quantitative pyrosequencing 
technology. The results, presented in Figure 7, showed that the methylation 
degree of CpG site +21 was significantly higher in 42,5% (23/54) of tumor 
samples compared to normal thyroid tissue. Methylation levels of CpG site +41 
were low and comparable among all the samples irrespective of their origin. 
Furthermore, by bisulfite genomic sequencing, 12 CpG sites located in the 
region +1242/+1543 within the downstream CpG island have been analyzed. 
This analysis showed that the average methylation of these sites was quite high 
(60%) but did not vary among the samples irrespective of gene expression and 
tissue origin (data not shown). Overall, this data suggests that the methylation 
state of CpG site +21 may contribute and represent a mark of Cl 2 gene 
silencing. 
 
4.4  
Immunohistochemical analysis of Cl 2 gene expression 
Detection of Cl 2 protein by immunohistochemical analysis allows a rapid and 
sensitive screening of thyroid pathological tissues and is amenable to regular use 
as a routine diagnostic test. This technique was therefore chosen for Cl 2 protein 
analysis using a commercial antibody against a Cl 2 specific peptide.  
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The results of the immunohistochemical study of 44 thyroid specimens are 
summarized in Table 4. Not only did they confirm a downregulation of Cl 2 
expression but also a translocation (nuclear > cytoplasm) in thyroid carcinoma, 
particularly in the follicular variant of PTC and in ATC.  
A positive nuclear signal was detected in normal thyroid, goiter and adenoma 
(Figure 8 A, B, C) whereas no nuclear staining was observed in papillary 
carcinoma (Figure 8 D) and in follicular carcinoma (Figure 8 D) and anaplastic 
carcinoma (Figure 8 E). In the last two cases the signal was predominantly 
cytoplasmic but the intensity was lower with respect to normal thyroid. In 
anaplastic carcinoma the signal of Cl 2 was lost in 6 out of 10 samples (Table 
4).For each case, sections were stained without the primary antibody and in all 
cases these controls were negative (data not shown). 
 
Histotype Samples Negative  1+ 
Positivity 
2+ 
 
3+ 
 Normal thyroid 2   1 N>>C 1 N>C 
Goiter 7 1 2 N>C 2 N 1 N 1 N>C 
Adenoma 7 1 3 N 2 N 1 N 1 N/C 
PTC 10 1 2 C 4 C 3 C 
FTC 10 3 4 C 2 C 1 C 
ATC 10 6 1 C 3 C  
Table 4. Results of immunohistochemical analysis. Samples were classified as negative when 
there was no staining with antibody anti-Cl 2, whereas for positivity has been used a scale with 
different intensity: 1+ weak, 2+ medium, 3+ strong. C and N indicate cytoplasmic  and nuclear 
localization, respectively. When a subcellular translocation of the signal was present, it was 
indicated with >. 
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Figure 8. Immunohistochemical analysis of Cl 2 protein expression in benign and malignant thyroid 
tissues. Panel A: normal thyroid (200 x), showing nuclear immunoreactivity Panel B: Goiter (200 x), 
showing nuclear immunoreactivity, (inset shows 400 x magnification). Panel C: Thyroid adenoma 
(200 x), also in this case, a nuclear positivity was observed, (inset shows 400 x magnification). Panel 
D: Thyroid papillary carcinoma (200 x), negative for protein expression. Panel E: Thyroid follicular 
carcinoma (200 x), showing absent of Cl 2 protein expression. Panel F: An anaplastic thyroid 
carcinoma (200 x), showing no Cl 2 protein expression  
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4.5 
 Cl 2 expression is also downregulated in ovary, colorectal and breast 
carcinomas 
The next step of my work has been to verify whether the downregulation of Cl 2 
expression is restricted to thyroid carcinomas, or is a more general event in the 
process of carcinogenesis. As shown in Figure 9, Cl 2 appears drastically 
downregulated in the large majority of ovary, breast and colon carcinomas. In 
particular, no expression at all was detected in 10 out of 20 ovary carcinomas. 
These results would suggest that the loss of Cl 2 expression might also have a 
role in the development of these human carcinomas.  
 
4.6  
Restoration of Cl 2  gene expression reverts the malignant phenotype of thyroid 
carcinoma cell lines. 
To determine whether the loss of Cl 2 gene expression affects thyroid 
carcinogenesis, I performed some functional analysis on two thyroid carcinoma 
cell lines, expressing very low level of mRNA of Cl 2, in which the expression 
was restored. To this aim I first carried out a growth curve on FRO cells stable 
expressing the Cl 2 gene (FRO-Cl2-B and FRO-Cl2-E) and, as shown in Figure 
10, they grew with a significantly slower rate in comparison to the untransfected 
(FRO) and p3XFLAG-CMV.10  transfected cells (FRO E.V.). 
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Figure 9. Expression analysis on Ovary (A), Colorectal (B) and Breast (C) carcinomas of Cl 2 
mRNA. Values are expressed in fold-change in a logarithmic scale with respect to a pool of 
normal samples which equaled 1.. In panel A value of fold-change-axis was arbitrary cut at the 
same value of the panels B and C. 
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Figure 11. Colony Formation assay. Restoration of Cl 2 gene in two different human thyroid 
carcinomas cell lines reduces their ability to form colony in culture dish. 
Moreover, I have analyzed the growth potential of human thyroid carcinoma cell 
lines and, as shown in Figure 11, FRO cells stable exprimenting Cl 2 gene 
generated a lower (less than 50%) number of colonies than cells transfected with 
the backbone vector did . 
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Figure 10. Growth curve of FRO-Cl 2 stable clones (B) and (E), untransfected FRO cells 
(FRO) and transfected with empty vector  (E.V.). After a 5 day observation the number of cells 
expressing Cl 2 gene was more than 2 times less with respect to control. 
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4.7  
The restoration of the Cl2 expression Cl2 gene inhibits the growth of  KAT-4 
thyroid carcinoma cell line in semisolid medium. 
Consistent results were obtained with a soft agar assay that measured the cell’s 
ability to grow in three-dimensional environment, performed using the KAT-4-
Cl 2 cells and KAT-4-E.V. cells. The growth of cell colonies was monitored for 
three weeks. After just one week, microscope observation revealed the formation 
of large colonies in plates where the KAT-4 cells transfected with the backbone 
vector were seeded. Conversely, no colonies could be detected in the plates that 
contained the KAT-4 cells where Cl 2 gene was restored. After three weeks the 
colonies of both plates were photographed and counted. As shown in Figure 12, 
the restoration of the Cl 2 drastically reduces the ability of the FRO cells to grow 
in agar. Indeed, the number of colonies formed by the KAT-4 cells expressing Cl 
2 was much lower in comparison to those generated by the empty vector-
transfected KAT-4 cells, and also the size of these colonies was small with the 
presence of apoptotic-like effect (Figure 12 A). 
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4.8  
Cl 2 affects the cell motility in vitro. 
I measured the effect that Cl 2 restoration has on the cell mobility, an important 
characteristic which marks a malignant phenotype. I performed a migration assay 
in bi-dimensional environment using the transwell system, and a wound healing 
assay. As shown in Figure 13 the ability of FRO-E.V. to invade and cross the 
Figure 12. Soft agar assay. Panel A: KAT-4 cells transfected with Cl 2 gene lose their 
ability to grow in a semi-solid medium (detached form culture disk). Panel B: 
Histograms represent the number of colony detected by a microscopy observation.  
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polycarbonate Nucleopore filters was higher respect to FRO-Cl 2 cells where the 
expression was re-established. To quantify the invasive capacity of both cells 
systems I measured by spectrophotometer the amount of dye that the cells had 
retained after the staining with crystal violet (see materials and methods for 
details). The ability of FRO-Cl 2 cells to cross the membrane was 60% lower 
with respect to FRO-E.V. cells. Consistent results were also obtained with 
wound healing assay. FRO-E.V. cells have a greater ability to migrate and to fill 
the gap generated in the cells monolayer. This is due to the high malignant 
phenotype that characterized this kind of cell lines . As shown in Figure 14, the 
cells where Cl 2 gene was re-expressed, the capability to move is much lower, in 
fact the FRO-Cl 2 cells fill the gap just as result of cellular division and not as 
cellular movement. Another important evidence that has been possible to verify 
looking at the FRO-Cl 2 cells was the shape. While the FRO-E.V. or FRO 
parental cells have a mesenchymal-like shape  (Figure 14 B and D), the FRO-Cl 
2 show a baso-apical polarity that is typical of epithelial cells (Figure 14 A and 
C). This change in the phenotype may have a crucial role in the migration and in  
the metastatic process. 
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Figure 13. Invasion Assay.Transwells in panel A contain FRO-E V cells, whereas 
transwells in panel B contain FRO-Cl 2 cells. As demonstrated by the weaker 
staining of transwells in lane B, FRO-Cl 2 cells have a reduced ability to invade 
the membrane of transwells. C and D are optical microscopy pictures of the 
transwells containing FRO-E V cells and FRO-Cl 2 cells respectively. 
Figure 14 In vitro wound healing assay. Pictures A and C : FRO-Cl 2 cells. Pictures B 
and D: FRO-E V cells. Cells in A and B were photographed immediately after 
scratch. Cells in C and D were photographed after 20 hours. FRO-E V cells continue 
to maintain a higher mobility and therefore a more aggressive phenotype. 
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4.9  
Restoration of Cl 2 expression causes cell death. 
To understand the role of Cl 2 in cell growth control, I investigated the cell cycle 
phase distribution of FRO cells transient transfected with Cl 2 gene through flow 
cytometric analysis. 
As shown in Figure 15, flow cytometric analysis revealed a significant shift of 
the DNA profile to a sub G1 position.  FRO cells expressing Cl 2 present a major 
percentage of counts in the sub G1 position as compared to FRO-E.V. cells, 27% 
and 6% respectively. Consistently, a TUNEL assay showed positive staining 
(red) for the Cl 2 transient transfected FRO cells, but not for the cells transfected 
with empty vector (Figure 16). Therefore, these results not only support a role 
for the Cl 2 gene in the inhibition of cell invasiveness, but also seem to confirm 
its role in the process of apoptosis. 
 
 
 
 
 
 
Figure 15. Cell Cycle analysis of FRO cell lines transient transfected with  pCMV.10 
vector (FRO-E V) and with pCMV.10-Cl 2 (FRO Cl 2). Re-expression of Cl 2 causes 
an increment of cells in sub G1 phase. 
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Finally, to investigate the role of Cl 2 in tumorigenicity I evaluated the effect of 
Cl 2 protein on the malignant transformed phenotype by analyzing the 
anchorage-independent growth in athymic mice. 
I injected 1 x 107 FRO-Cl 2 cells in athymic mice: no development of xenograft 
tumors was observed even after 6 weeks, whereas they appeared after 3-4 weeks 
when the same number of untransfected FRO cells was injected. The same result 
was observed when the same experiments were performed using the KAT-4 cell 
line. 
These results clearly indicate a role of the Cl 2 gene in the process of apoptosis 
and then, in the progression of thyroid carcinogenesis, of the FRO cells where 
the expression of the Cl 2 gene was restored. 
A B
Fig 16. TUNEL assay on FRO cell lines transient treansfected with pCMV10-Cl 2 (A) and 
with empty vector (B). Virtual pictures of apoptotic nucleus were obtained by merging 
DAPI stained nucleus (blue) with red fluorescence of DNA strand breaks labelled with 
tetra-methyl-rhodamine-dUPT. 
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4.10  
Generation and characterization of Cl 2 null mice 
We used gene targeting techniques in embryonic stem (ES) cells to generate a 
null mutation at the murine Cl 2 genomic locus. We deleted exon I, intron1 and 
exon 2 which contain the start site of murine Cl 2 gene and replaced them with a 
neomycin-resistant gene. Both heterozygous and homozygous mutant mice were 
viable and fertile. PCR and RT-PCR analysis, shown in Figure 16, confirmed the 
lack of expression of  Cl 2 in  null mice. 
 
 
 
 
Clinical and molecular analysis by Cl 2-/- and Cl 2+/- mice seem to confirm the 
tumor suppressor role of the Cl 2 gene in thyroid neoplasias. In fact, four out of 
16 mice analyzed developed thyroid adenomas and two mice showed ovary 
carcinomas (Figure 18). 
ko
wt
+/+ +/- -/-
DNA from mice tails
PCR
b-Actina
+/- -/-+/+
RNA from mice spleen
RT-PCR
Cl 2/CCDC80
Figure 16. Cl 2 knock-out mice screening. The genotyping of Knock-out Cl 2 mice 
was performed using PCR and RT-PCR techniques. 
 
A B 
Figure 18. Representative neoplatic lesions in Cl 2 ko mice. A thyroid adenoma. B ovary carcinomas. 
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Furthermore, I have also analyzed the growth rate of mouse embryonic 
fibroblasts (MEF) carrying one and two impaired Cl 2 alleles. As shown in 
Figure 19, MEFs null for Cl 2 have a higher proliferation rate than the wild type 
MEFs, whereas the Cl 2+/- MEFs show an intermediate behavior suggesting a 
negative role of the Cl 2 protein in the growth of these cells. Equally, MEFs null 
for Cl 2 showed a much lower rate of apoptosis in comparison with the wild type 
and Cl 2+/- MEFs (Figure 20). 
 
 
 
 
 
 
 
 
Finally, to verify in vivo the hypothesis of a tumor suppressor function for Cl 2 I 
crossed Cl 2-/-, Cl 2+/- and WT mice with RET/PTC1 knock-in mice which 
developed thyroid tumor easily (Santoro M, 1996). The results confirm that the 
action of Cl 2 is crucial for thyroid cancerogenesis. Indeed, as shown in Figure 
21, the thyroid tumor of Cl 2-/-_RET/PTC1 mice was enormous when compared 
with thyroid of RET/PTC1 transgenic mice. Moreover, as reported in Table 5 
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Figure 19. MEFs growth curve. Knock-out MEFs 
for Cl 2 gene (-/-) grow faster respect WT (+/+). 
Heterozygous phenotype (+/-) shows an 
intermediate behavior. 
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Figure 20. Cell Cycle analysis on MFSs coming 
from WT mice (+/+), Cl 2 +/- and Cl 2 -/-. 
WT MEFs showed a subG1 phase (apoptotic 
nucleus) 10% higher with respect +/- and -/- 
MEFs, whereas the G1 phase was 10% less with 
respect to other genotypes. 
  49 
these types of tumors not only have big dimension but also present 
histopathological characteristics more aggressive with infiltrating and solid 
pattern that are rarely found in classical PTC mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. Mouse thyroid tumors. A: Representative thyroid tumor from an RET/PTC1 knock-in 
mouse. B: Representative thyroid tumor developed from a considerable number of mice originated 
by the cross of RET/PTC1 knock-in mouse with Cl 2 knock-out mouse. 
 
Table 5. Summary of histopathological characteristics developed by RET/PTC1-Cl 2 mice. 
Genotype RET/PTC1 Cl 2 +/+ RET/PTC1 Cl 2 +/- RET/PTC1 Cl 2 -/-     Total Mice 5 10 8     Pathological lesions    Thyroid Carcinoma 3 5 7 Iperplasia 1 0 1 Normal thyroid 1 5 0     Diagnosis    PTC 3 2 1 PTC solid pattern 0 3 3 PTC infiltrating 0 0 3     Dimension range    1-2 mm 1 4 2 2-5 mm 4 4 4 5-10 mm 0 2 2     Sex    Female 2 6 3 Male 3 4 5      
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DISCUSSION 
Thyroid carcinoma is a common malignant tumor with a good prognosis if 
timely diagnosed. The enlargement number of emerging candidate diagnostic 
thyroid cancer markers can improve the clinical treatment of thyroid cancer. To 
day, several oncogenes have been demonstrated to be involved in human thyroid 
carcinomas, particularly in papillary histotype, but little is known with regard to 
tumor suppressor genes. In addition, about 20-25% of carcinomas affecting the 
thyroid gland seem not to present mutations or expression changes of well-
known oncogenes. Therefore, other mechanisms such as up- or down-regulation 
of transcription level of some genes may have an important role in thyroid 
carcinogenesis. 
Recently (Visconti R, 2003) was reported the identification of a gene, named Cl 
2, and subsequently CCDC80, downregulated in a panel of few cases of thyroid 
carcinomas, even though its expression was enormously upregulated in rat 
thyroid cells infected with the E1A gene of Adenovirus. To explain this 
contrasting behavior of Cl 2 expression in PC E1A cell lines and thyroid 
carcinoma, it was hypothesized that abundant Cl 2 mRNA level and 
consequently elevated levels of protein could contribute to the high apoptotic 
rate of PC E1A cells, suggesting a tumor suppressor role for Cl2 gene. 
The results reported in the present study seem to support a role of Cl 2 gene in 
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human thyroid carcinogenesis through its involvement in the control of cell 
growth, invasion and apoptosis. Indeed, I confirmed, by qRT-PCR, the decrease 
in Cl 2 expression in thyroid carcinoma analyzing a large number of cases. A 
severe reduction of Cl 2 mRNA was observed in the follicular variant of 
papillary carcinomas, in which the average down-regulation value was 60 fold. 
Moreover, in some samples of this histotype Cl 2 specific mRNA was almost 
undetectable. A drastic reduction of Cl 2 was also present in the classic form of 
papillary carcinoma, in follicular and anaplastic carcinomas with an average 
down-regulation value of 15-20 fold. Interesting results were obtained when Cl 2 
protein expression was analyzed by immunohistochemistry. I found that Cl 2 
protein in thyroid carcinomas presents not only a downregulation but also a 
different localization. In fact, in normal thyroid tissue the signal of 
immunostaining is clearly nuclear but becomes cytoplasmatic in papillary and 
follicular carcinomas disappearing in almost all anaplastic carcinomas. LOH at 
the Cl 2 locus and an increase of the methylation status of single CpG close to 
TSS seem to account for the reduced expression of Cl 2. Indeed, LOH at Cl 2 
locus was observed in 50% of the follicular variants of papillary carcinomas, and 
was well correlated with the downregulation of Cl 2 gene expression. As far as 
the methylation status of the Cl 2 promoter is concerned, although a dense CpG 
island located in the second exon was not differentially methylated, a single CpG 
site very close to TSS (+21) was hypermethylated in tumors (42,5%) compared 
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to normal tissues. Even if the region surrounding the TSS is very poor in CpG 
sites, the differential methylation of a single CpG sites located in a strategic 
position (+21) may potentially affect the binding of methyl-binding proteins at 
promoter region and, as a consequence, may have a consistent impact on the 
transcriptional potential of the gene. Moreover, unexpectedly, and at odds with 
the recent publication that indicates a downregulation of Cl 2 expression by beta-
catenin, no inverse correlation, was found between beta-catenin and Cl 2 
expression. I observed that the decrease in Cl 2 expression is more marked where 
the beta-catenin expression is not increased. Furthermore, the significant Cl 2 
downregulation in human breast, colon ,and particularly, ovarian carcinoma 
propose it as a general event in the process of carcinogenesis. Further evidence 
supports the relation between Cl 2 gene and carcinogenesis coming from the 
restoration of Cl 2 expression in human thyroid carcinoma cell lines that cause a 
drastic reduction of cell growth rate. I also showed an inhibitory effect of Cl 2 
overexpression on cell invasion. Moreover, a cytofluorimetric assay 
demonstrated a shift of the DNA profile to a sub G1 position, that is indicative of 
apoptosis, when the expression of Cl 2 was restored in thyroid carcinoma cell 
lines. Then, the ability of Cl 2 to induce apoptosis was confirmed by a TUNEL 
assay. Furthermore, the cells re-expressing the Cl 2 lost the typical markers of 
neoplastic transformation since they were not able to grow efficiently in 
semisold medium and did not induce tumors when injected into athymic mice. 
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The generation of mice knock out for the Cl 2 gene seemed to confirm a tumor 
suppressor role for this gene. Indeed, MEFs Cl 2-/- have a higher proliferation 
rate with respect to the wild type, whereas the MEFs+/- show an intermediate 
behaviour. Moreover, the MEFs KO for Cl 2 were less susceptible to apoptosis 
in comparison to the MEFs+/- and +/+. In addition, these mice developed thyroid 
adenomas with a significant frequency, an event occurring very rarely in normal 
wild type (Biancifiori C, 1979), and three ovarian carcinomas. This last result is 
also consistent with the drastic loss of Cl 2 expression in human ovarian 
carcinomas. Finally, I demonstrated through mouse models, that the loss of Cl 2 
gene is crucial for thyroid cancerogenesis. In fact, crossing RET/PTC1 knock-in 
mice with Cl 2 knock-out mice I observed a synergy between oncogenetic ability 
of RET/PTC1 oncogene and loss of oncosuppressor capacity of Cl 2. The thyroid 
glad of mice resulting by the cross showed biggest dimensions due to neoplastic 
transformation with very relevant histopathological lesions. In conclusion, all the 
data reported here indicate a critical role of the loss of CL 2 expression in the 
process of thyroid carcinogenesis and likely other tissues. 
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